Adverse reactions to vaccines.

Ann Allergy Asthma Immunol 2009 Oct;103(4 Suppl 2):S1-14

Download full-text PDF

Source
http://dx.doi.org/10.1016/s1081-1206(10)60350-xDOI Listing
October 2009

Publication Analysis

Save 15% Survey

Similar Publications

Influence of a COVID-19 vaccine's effectiveness and safety profile on vaccination acceptance.

Proc Natl Acad Sci U S A 2021 03;118(10)

Clinical Excellence Research Center, Stanford University School of Medicine, Stanford, CA 94305.

Although a safe and effective vaccine holds the greatest promise for resolving the COVID-19 pandemic, hesitancy to accept vaccines remains common. To explore vaccine acceptance decisions, we conducted a national survey of 1,000 people from all US states in August of 2020 and a replication in December of 2020. Using a 3 × 3 × 3 factorial experimental design, we estimated the impact of three factors: probability of 1) protection against COVID-19, 2) minor side effects, and 3) a serious adverse reactions. Read More

View Article and Full-Text PDF

First-in-human study of the cancer peptide vaccine, TAS0313, in patients with advanced solid tumors.

Cancer Sci 2020 Dec 7. Epub 2020 Dec 7.

Department of Experimental Therapeutics, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.

TAS0313, a novel cancer vaccine cocktail, was developed to overcome the disadvantages of previously developed short and long peptide vaccines; it comprises several long peptides targeting multiple cancer antigens. We evaluated TAS0313 monotherapy in Japanese patients with advanced solid tumors for which no other therapies were available. In the dose-finding cohort, patients received TAS0313 (9 mg or 27 mg) on Days 1, 8, and 15 of Cycles 1 and 2, and then on Day 1 of each subsequent 21-day cycle. Read More

View Article and Full-Text PDF
December 2020

Immunotherapy for COVID-19: Evolving treatment of viral infection and associated adverse immunological reactions.

Authors:
Jeffrey S Putter

Transfus Apher Sci 2021 Feb 13:103093. Epub 2021 Feb 13.

Medical Biomechanics Inc., San Diego County, CA, United States. Electronic address:

This review on COVID-19 immunotherapy enables a comparative analysis of the short-list of currently approved major vaccines. These include the Pfizer and Moderna first mRNA vaccines under FDA purview and the Oxford/AstraZeneca simian adenovirus-vectored vaccine (under UK-MHPRA guidance), all produced in record time, being safe and effective. The Pfizer and Moderna double dose vaccines have the clear edge in treatment efficacy, being in the 90% range compared to AstraZeneca in the average 70%. Read More

View Article and Full-Text PDF
February 2021

Safety and immunogenicity of high doses of quadrivalent influenza vaccine in children 6 months through <18 years of age: A randomized controlled phase II dose-finding trial.

Vaccine 2021 Feb 18. Epub 2021 Feb 18.

Sanofi Pasteur, Research and Development, Marcy L'Etoile, France. Electronic address:

Quadrivalent high-dose inactivated influenza vaccine (Fluzone® High-Dose Quadrivalent, IIV4-HD) was licensed in the USA in 2019 for adults ≥ 65 years of age. This Phase II study examined safety and immunogenicity of 3 dose formulations of IIV4-HD in healthy children. In a randomized, modified double-blind, active-controlled trial in the USA and Canada, 661 children aged 6 months through < 18 years received 1 or 2 doses intramuscularly of standard-dose quadrivalent influenza vaccine (IIV4-SD; 15 µg HA/strain), IIV4-HD at 3 dose levels (30, 45, and 60 µg HA/strain), or adjuvanted trivalent influenza vaccine (aIIV3, 7. Read More

View Article and Full-Text PDF
February 2021

Antigen-based multiplex strategies to discriminate SARS-CoV-2 natural and vaccine induced immunity from seasonal human coronavirus humoral responses.

medRxiv 2021 Feb 12. Epub 2021 Feb 12.

Sensitive and specific SARS-CoV-2 antibody assays remain critical for community and hospital-based SARS-CoV-2 sero-surveillance. With the rollout of SARS-CoV-2 vaccines, such assays must be able to distinguish vaccine from natural immunity to SARS-CoV-2 and related human coronaviruses. Here, we developed and implemented multiplex microsphere-based immunoassay strategies for COVD-19 antibody studies that incorporates spike protein trimers of SARS-CoV-2 and the endemic seasonal human coronaviruses (HCoV), enabling high throughout measurement of pre-existing cross-reactive antibodies. Read More

View Article and Full-Text PDF
February 2021